In addition, reproterol significantly ameliorated HFD-induced obesity, glucose tolerance, and insulin resistance (Fig. 8k and Fig. S10a, b), reduced glycogen deposition (Fig. S10c) and reduced serum insulin levels (Fig. S10d), unaltered liver cholesterol contents (Fig. 8l) and serum cholesterol and triglyceride levels (Fig. S10e, f), with a marked suppression of liver glucose-6-phosphatase expression (Fig. S10g). Here, INS is linked to Obesity.